EVERY MELANOMA IS UNIQUE.

Merlin logo

The Merlin™ Test is a unique tool for your personalized melanoma care.

Current treatment decisions for sentinel lymph node biopsy referral are made based on clinicopathologic factors such as patient’s age, Breslow thickness and ulceration. However, these variables do not always provide complete insights of the melanoma.

With the Merlin Test, it is possible to take a deeper look into the biology of your melanoma by analyzing the expression of 8 specific genes involved in processes related to cancer metastasis and melanosome biogenesis – alongside the clinicopathologic variables patient’s age and Breslow thickness.

The Merlin Test helps in identifying primary cutaneous melanoma patients who have a low risk of having nodal metastasis and may therefore forgo a sentinel lymph node biopsy procedure.

The Merlin Test has been developed in partnership by SkylineDx and the Mayo Clinic (USA) and has been validated in multiple multicenter clinical trials in the United States and in Europe.

For Physicians

For Patients

Melanoma is one of the most common cancers in Europe.

>0

New Melanoma Cases
EVERY YEAR

Over the last 30 years, melanoma incidence has risen by 237%1 and every year, more than 150,000 new cases2 are diagnosed within Europe.

Early diagnosis, appropriate testing, and accurate staging are essential to the care and management of every patient.

  1. Melanoma Patient Network EU. www.melanomapatientnetworkeu.org
  2. WHO The Global Cancer Observatory – March 2021 https://gco.iarc.fr/today/data/ factsheets/populations /908-europe-fact-sheets.pdf